Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Rhea-AI Summary
Citius Pharmaceuticals (Nasdaq: CTXR) reported fiscal Q3 2026 results, highlighting initial commercial traction for LYMPHIR, launched by majority-owned subsidiary Citius Oncology (Nasdaq: CTOR). For the three months ended June 30, 2026, Citius recorded $1.5 million in revenue and gross profit of $1.0 million, a ~67% gross margin. Nine-month revenue reached $7.1 million with a ~77% gross margin. Cash and cash equivalents were $17.0 million at June 30, 2026.
LYMPHIR availability expanded to 44 institutions, institutional vial orders rose 31%, and new ordering institutions increased 80%. Citius Oncology completed nationwide deployment of 29 commercial and medical affairs professionals. Citius reported a Q3 2026 net loss applicable to common stockholders of $8.9 million and a nine‑month net loss of $38.3 million.
Positive
- $7.1 million LYMPHIR revenue in nine months of fiscal 2026, from zero in 2025
- Q3 2026 revenue of $1.5 million with ~67% gross margin
- Nine‑month 2026 gross profit of $5.5 million and ~77% gross margin
- R&D expenses reduced to $4.3 million for nine months 2026 from $7.5 million
- Cash and cash equivalents increased to $17.0 million from $4.3 million at Sept 30, 2025
- Financing inflows: ~$4.5 million direct offering, $9.7 million warrant exercises, $10.0 million term loan tranche
- LYMPHIR available at 44 institutions; July institutional orders reached 383 vials, highest month to date
- Phase 1 DLBCL study reported 86% ORR and 57% CR with no dose‑limiting toxicities
Negative
- Net loss applicable to common stockholders of $8.9 million in Q3 2026
- Nine‑month 2026 net loss applicable to common stockholders of $38.3 million
- Nine‑month 2026 operating cash outflow of $23.0 million
- General and administrative expenses rose to $38.3 million for nine months 2026 from $14.6 million
- Includes non‑recurring $19.7 million contract cancellation charge recognized in March 2026
- Common shares outstanding increased to 27.45 million from 18.07 million at Sept 30, 2025
- New notes payable of $6.4 million and related interest expense of $0.4 million for nine months 2026
News Explained
The financing added cash but also debt and shares; $10.0 million of a facility of up to $25.0 million was funded by June 30, 2026.
Citius Pharmaceuticals reported fiscal third-quarter results; its financing update records a closed offering, exercised warrants, and a funded loan tranche, bringing in cash while changing the capital structure through debt and issued shares.
Common shares issued and outstanding were 27,452,570 at
The April 2026 transaction was a registered direct offering, meaning a negotiated sale of registered securities to selected investors; the company reported approximately
The loan facility is described as up to
Market reaction after 3Q26 earnings report: CTOR -19.76%
Following this news, CTOR has declined 19.76%, reflecting a significant negative market reaction. Our momentum scanner has triggered 14 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $0.73. Trading volume is very high at 4.9x the average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 15 | 2Q26 earnings report | Negative | -13.9% | Quarterly loss increased alongside a non-recurring contract cancellation charge. |
| May 15 | 2Q26 earnings report | Negative | -13.9% | Parent company reported higher losses and additional financing requirements. |
| Dec 23 | FY25 earnings report | Negative | -9.8% | Commercial launch progress accompanied substantial financing and an annual net loss. |
| Dec 23 | FY25 earnings report | Negative | -9.8% | Launch milestones were accompanied by a $39.7 million net loss. |
| Aug 12 | 3Q25 earnings report | Negative | +5.9% | Pre-launch results showed limited cash and a higher quarterly net loss. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific earnings history included negative reactions of -13.95% and -9.84%, alongside one positive reaction of 5.92%, indicating predominantly negative but non-uniform responses.
Key Terms
objective response rate medical
complete response medical
dose-limiting toxicities medical
senior secured term loan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Expanded LYMPHIR commercial and medical affairs organizations deployed nationwide
"The LYMPHIR launch continued to build momentum in our fiscal third quarter and remains the primary driver of our business. The number of institutional vial orders increased, new institutions placed orders, and LYMPHIR became available at 44 leading academic oncology centers, NCCN institutions and community infusion centers. These indicators demonstrate meaningful progress in formulary access and treatment-driven demand as physicians gain familiarity with LYMPHIR's differentiated clinical profile," said Leonard Mazur, Chairman and Chief Executive Officer of Citius Pharma and Citius Oncology.
"Following the quarter end, we completed the nationwide deployment of Citius Oncology's expanded commercial and medical affairs teams, which now total 29 professionals. These teams are positioned to leverage the existing platform established to support LYMPHIR's success, including patient hub services, marketing, reimbursement support, and market access. We believe our expanded organization will facilitate increased engagement with priority treatment centers, support formulary adoption and broaden access for eligible patients as the launch matures," added Mazur.
"We also continued to advance LYMPHIR's longer-term value proposition. Phase 1 investigator-initiated data presented at ASCO demonstrated encouraging clinical activity and durable responses for LYMPHIR in combination with pembrolizumab in heavily pre-treated gynecologic malignancies. Additionally, Phase 1 data of LYMPHIR administered prior to CAR-T therapy in high-risk relapsed or refractory DLBCL, presented at the 2026 ASTCT® & CIBMTR® Tandem Meetings, showed an
Fiscal Third Quarter 2026 Business Highlights and Subsequent Developments
- Continued commercial momentum for LYMPHIR, with availability in 44 institutions, including academic oncology centers, leading National Comprehensive Cancer Network (NCCN) institutions and community infusion centers;
- Increased the number of new institutions ordering LYMPHIR by
80% and grew institutional vial orders from wholesalers by31% ; - Drove continued institutional demand growth in July, with 383 vials ordered by institutions from wholesalers, the largest vial order month to date;
- Secured near universal payer coverage, with no reimbursement denials or preauthorization barriers reported to date;
- Expanded Citius Oncology's commercial organization by 21 commercial field-based professionals and added eight medical science liaisons, with nationwide deployment completed in August 2026 through EVERSANA, the Company's exclusive commercialization partner;
- Advanced Phase 1 investigator-initiated trials:
- Data were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting evaluating LYMPHIR in combination with pembrolizumab in recurrent or refractory gynecologic malignancies:
24% overall response rate (ORR) and a48% clinical benefit rate, and- median progression-free survival of 20.5 months among patients achieving clinical benefit;
- Data were presented at the 2026 ASTCT® & CIBMTR® Tandem Meetings evaluating LYMPHIR administered prior to CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL):
86% ORR, including57% complete response (CR) and29% partial response (PR),- LYMPHIR was well-tolerated with no dose-limiting toxicities observed;
- Data were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting evaluating LYMPHIR in combination with pembrolizumab in recurrent or refractory gynecologic malignancies:
- Closed a registered direct offering in April 2026 for net proceeds of approximately
$4.5 million - Received approximately
$9.7 million $10.0 million $25.0 million - Citius Oncology appointed Jonathan Peri, Ph.D., J.D., as an independent director, effective August 10, 2026, expanding the board to nine members.
Fiscal Third Quarter 2026 Financial Highlights and Subsequent Developments
- Cash and cash equivalents of
$17.0 million - Revenues of
$1.5 million $7.1 million - Gross profit of
$1.0 million 67% , and$5.5 million 77% ; - Research and development expenses of
$1.1 million $1.6 million $4.3 million $7.5 million - General and administrative expenses of
$6.1 million $4.4 million $38.3 million $14.6 million $19.7 million - Stock-based compensation expense of
$3.8 million $2.7 million $11.9 million $7.9 million - Net loss applicable to common stockholders of
$8.9 million $(0.34) $8.8 million $(0.80) $38.3 million $(1.64) $29.5 million $(3.27)
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately
About Citius Oncology, Inc.
Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to regain compliance with Nasdaq's continued listing standards; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; our ability to obtain, perform under and maintain financing, strategic and third party agreements and relationships, including obtaining a new bulk drug substance supplier; our ability to secure strategic partnerships and expand international access to LYMPHIR; our ability to use the latest technology to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our ability to obtain regulatory approval for and commercialize or enter into strategic partnerships with respect to Mino-Lok and Halo-Lido; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related to LYMPHIR; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; risks relating to the results of research and development activities, including those from any new pipeline assets; our ability to procure cGMP commercial-scale supply; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov, including in Citius Pharma's Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025 and as amended on January 28, 2026. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113
Media Contact:
STiR-communications
Greg Salsburg
Greg@STiR-communications.com
– Financial Tables Follow –
CITIUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) | ||||||||
June 30, | September 30, | |||||||
2026 | 2025 | |||||||
ASSETS | ||||||||
Current Assets: | ||||||||
Cash and cash equivalents | $ | 17,007,523 | $ | 4,252,290 | ||||
Accounts receivable, net of allowances | 686,235 | - | ||||||
Inventory | 22,625,945 | 22,286,693 | ||||||
Prepaid expenses | 3,011,660 | 1,395,490 | ||||||
Total Current Assets | 43,331,363 | 27,934,473 | ||||||
Operating lease right-of-use asset, net | 753,039 | 818,694 | ||||||
Deposits | 38,062 | 38,062 | ||||||
In-process research and development, net of accumulated amortization | 88,785,938 | 92,800,000 | ||||||
Goodwill | 9,346,796 | 9,346,796 | ||||||
Total Other Assets | 98,170,796 | 102,184,858 | ||||||
Total Assets | $ | 142,255,198 | $ | 130,938,025 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current Liabilities: | ||||||||
Accounts payable | $ | 8,037,899 | $ | 13,693,692 | ||||
License payable | 15,650,000 | 22,650,000 | ||||||
Accrued expenses | 25,913,962 | 4,190,253 | ||||||
Accrued compensation | 1,871,320 | 3,292,447 | ||||||
Note payable | - | 1,000,000 | ||||||
Operating lease liability | 176,170 | 88,348 | ||||||
Total Current Liabilities | 51,649,351 | 44,914,740 | ||||||
Deferred tax liability | 7,696,443 | 7,770,760 | ||||||
Notes payable, net of deferred financing fees | 6,410,161 | - | ||||||
Operating lease liability – noncurrent | 590,787 | 724,925 | ||||||
Total Liabilities | 66,346,742 | 53,410,425 | ||||||
Commitments and Contingencies | ||||||||
Stockholders' Equity: | ||||||||
Preferred stock - | - | - | ||||||
Common stock - | 27,452 | 18,068 | ||||||
Additional paid-in capital | 343,704,577 | 306,336,239 | ||||||
Accumulated deficit | (277,118,897) | (238,804,129) | ||||||
Total Citius Pharmaceuticals, Inc. Stockholders' Equity | 66,613,132 | 67,550,178 | ||||||
Non-controlling interest | 9,295,324 | 9,977,422 | ||||||
Total Equity | 75,908,456 | 77,527,600 | ||||||
Total Liabilities and Equity | $ | 142,255,198 | $ | 130,938,025 | ||||
CITIUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2026 AND 2025 (Unaudited) | ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
June 30, | June 30, | June 30, | June 30, | |||||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||||||
Revenues | $ | 1,493,788 | $ | — | $ | 7,105,197 | $ | — | ||||||||
Cost of revenues | (491,843) | — | (1,609,929) | — | ||||||||||||
Gross Profit | 1,001,945 | — | 5,495,268 | — | ||||||||||||
Operating Expenses | ||||||||||||||||
Research and development | 1,053,869 | 1,621,325 | 4,287,106 | 7,514,888 | ||||||||||||
Amortization of in-process research and development | 1,720,312 | — | 4,014,062 | — | ||||||||||||
General and administrative | 6,149,173 | 4,447,008 | 38,261,001 | 14,626,882 | ||||||||||||
Stock-based compensation – general and administrative | 3,810,665 | 2,719,674 | 11,879,167 | 7,946,529 | ||||||||||||
Total Operating Expenses | 12,734,019 | 8,788,007 | 58,441,336 | 30,088,299 | ||||||||||||
Operating Loss | (11,732,074) | (8,788,007) | (52,946,068) | (30,088,299) | ||||||||||||
Other Income (Expense) | ||||||||||||||||
Interest income | 116,691 | 20,637 | 215,372 | 56,658 | ||||||||||||
Gain on sale of | — | — | 3,833,277 | — | ||||||||||||
Amortization of deferred financing costs | (179,492) | — | (179,492) | — | ||||||||||||
Interest expense | (231,732) | (172,262) | (420,301) | (172,262) | ||||||||||||
Total Other Income (Expense), Net | (294,533) | (151,625) | 3,448,856 | (115,604) | ||||||||||||
Loss before Income Taxes | (12,026,607) | (8,939,632) | (49,497,212) | (30,203,903) | ||||||||||||
Income tax expense (benefit) | (107,347) | 264,240 | (74,317) | 792,720 | ||||||||||||
Net Loss | (11,919,260) | (9,203,872) | (49,422,895) | (30,996,623) | ||||||||||||
Net loss attributable to non-controlling interest | 3,056,417 | 414,000 | 11,108,127 | 1,522,000 | ||||||||||||
Net loss applicable to common stockholders | $ | (8,862,843) | $ | (8,789,872) | $ | (38,314,768) | $ | (29,474,623) | ||||||||
Net Loss Per Share - Basic and Diluted | $ | (0.34) | $ | (0.80) | $ | (1.64) | $ | (3.27) | ||||||||
Weighted Average Common Shares Outstanding | ||||||||||||||||
Basic and diluted (includes pre-funded warrants) | 26,169,589 | 11,006,896 | 23,343,869 | 9,020,356 | ||||||||||||
CITIUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED JUNE 30, 2026 AND 2025 (Unaudited) | ||||||||
2026 | 2025 | |||||||
Cash Flows From Operating Activities: | ||||||||
Net loss | $ | (49,422,895) | $ | (30,996,623) | ||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Stock-based compensation expense | 11,879,167 | 7,946,529 | ||||||
Issuance of common stock for services | 107,510 | — | ||||||
Issuance of common stock warrant | 68,597 | — | ||||||
Amortization of in-process research and development | 4,014,062 | — | ||||||
Amortization of operating lease right-of-use asset | 65,655 | 152,212 | ||||||
Amortization of deferred financing costs | 179,492 | — | ||||||
Deferred income tax expense (benefit) | (74,317) | 792,720 | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net of allowances | (686,235) | — | ||||||
Inventory | (339,252) | (8,940,201) | ||||||
Prepaid expenses | (1,616,170) | 1,386,824 | ||||||
Accounts payable | (5,655,793) | 5,166,831 | ||||||
Accrued expenses | 19,961,209 | 8,506,648 | ||||||
Accrued compensation | (1,421,127) | 1,481,023 | ||||||
Operating lease liability | (46,316) | (167,911) | ||||||
Net Cash Used In Operating Activities | (22,986,413) | (14,671,948) | ||||||
Cash Flows From Investing Activities: | ||||||||
License fee payments | (7,000,000) | — | ||||||
Net Cash Used in Investing Activities | (7,000,000) | — | ||||||
Cash Flows From Financing Activities: | ||||||||
Proceeds from (repayment of) note payable and advance from employee | (1,000,000) | 1,300,000 | ||||||
Repayment of advance from employee | (300,000) | |||||||
Net proceeds from loan agreement | 9,635,000 | — | ||||||
Proceeds from exercise of warrants | 9,731,103 | — | ||||||
Deferred Financing Costs | (892,551) | — | ||||||
Proceeds from sale of Series A preferred stock | — | 100 | ||||||
Redemption of Series A preferred stock | — | (100) | ||||||
Net proceeds from common stock offerings | 25,268,094 | 16,509,194 | ||||||
Net Cash Provided By Financing Activities | 42,741,646 | 17,509,194 | ||||||
Net Change in Cash and Cash Equivalents | 12,755,233 | 2,837,246 | ||||||
Cash and Cash Equivalents - Beginning of Period | 4,252,290 | 3,251,880 | ||||||
Cash and Cash Equivalents - End of Period | $ | 17,007,523 | $ | 6,089,126 | ||||
Supplemental Disclosures of Cash Flow Information and Non-cash Transactions: | ||||||||
Interest paid | $ | 303,644 | $ | — | ||||
Operating lease right-of-use asset and liability recorded | $ | — | $ | 786,697 | ||||
Warrants issued for loan agreement included in deferred financing costs | $ | 749,280 | $ | — | ||||
Deferred financing costs included in accrued expenses | $ | 1,762,500 | $ | — | ||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-reports-fiscal-third-quarter-2026-financial-results-and-provides-business-update-302852124.html
SOURCE Citius Pharmaceuticals, Inc.